CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Alcon Research

ALC
$11.61B
Large Cap
NASDAQOphthalmic GoodsOphthalmology🇺🇸North AmericaFORT WORTH25.6K employees

Alcon Inc. (German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon is incorporated in the Canton of Fribourg, Switzerland, and its global headquarters are located in Geneva, but its main operational base is in Fort Worth, Texas, United States, where it employs about 4,500 people.

Website

Drugs in Pipeline

122

Phase 3 Programs

84

Upcoming Catalysts

2

Next Catalyst

May 15, 2026

10w

Market Overview

Stock performance and key metrics

ALC News
Catalyst Timeline

2 upcoming, 0 past

No catalysts found.

2 more catalysts beyond 14 days

Start a 48h free trial to see all upcoming catalysts

Pro
Drug Pipeline

Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution

Phase 3

Open-angle Glaucoma

Olopatadine Hydrochloride Ophthalmic Solution, 0.2%

Phase 3

Allergic Conjunctivitis

Travoprost 0.004% PQ ophthalmic solution

Phase 3

Pediatric Glaucoma

Olopatadine Hydrochloride Ophthalmic Solution Vehicle

Phase 3

Allergic Conjunctivitis

Moxifloxacin ophthalmic solution, 0.5%

Phase 3

Bacterial Conjunctivitis

Tobradex ST

Phase 3

Blepharitis

Aflibercept ophthalmic solution

Phase 3

Neovascular Age-Related Macular Degeneration

Nepafenac 1mg/ml eye drops, suspension

Phase 3

Cataracts

Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension

Phase 3

Open-angle Glaucoma

Travoprost ophthalmic solution, 0.003%

Phase 3

Open-Angle Glaucoma

Vehicle

Phase 3

Seasonal Allergic Rhinitis

Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution

Phase 3

Open-Angle Glaucoma

Brimonidine tartrate ophthalmic solution, 0.2%

Phase 3

Open-Angle Glaucoma

Triamcinolone Acetonide Injectable Suspension

Phase 3

Vitrectomy

Nepafenac Ophthalmic Suspension, 0.3%

Phase 3

Non-Proliferative Diabetic Retinopathy

Apraclonidine Hydrochloride Ophthalmic Solution

Phase 3

Ocular Redness

BETOPTIC S (betaxolol HCl)

Phase 3

Glaucoma

quinolone

Phase 3

Bacterial Conjunctivitis

Prednisolone acetate

Phase 3

Non-Proliferative Diabetic Retinopathy

AL-3862+timolol ophthalmic suspension

Phase 3

Glaucoma

Nepafenac ophthalmic suspension, 0.1% (NEVANAC)

Phase 3

Macular Edema

Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%

Phase 3

Bacterial Conjunctivitis

Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)

Phase 3

Glaucoma

Travoprost/Timolol Maleate Fixed Combination solution

Phase 3

Open-angle Glaucoma

Dexamethasone phosphate otic solution

Phase 3

Acute Otitis Externa

Latanoprost ophthalmic solution 0.005% (XALATAN®)

Phase 3

Open-angle Glaucoma

Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension

Phase 3

Open-angle Glaucoma

Olopatadine Hydrochloride Nasal Spray 0.6%

Phase 3

Allergic Rhinitis

Olopatadine 0.6% nasal spray

Phase 3

Perennial Allergic Rhinitis

Travatan

Phase 3

Glaucoma, Open-angle

Olopatadine Hydrochloride Ophthalmic Solution, 0.1%

Phase 3

Allergic Conjunctivitis

AL-60371 Vehicle

Phase 3

Acute Otitis Externa

AL-60371, 0.3% Otic Suspension

Phase 3

Acute Otitis Externa

Timolol maleate ophthalmic solution, 0.5%

Phase 3

Open-angle Glaucoma

Anecortave Acetate Sterile Suspension, 60 mg/mL

Phase 3

Open-angle Glaucoma

BSS Plus

Phase 3

Cataract

Latanoprost 0.005% Ophthalmic Solution (XALATAN)

Phase 3

Open-Angle Glaucoma

Nepafenac Ophthalmic Suspension, 0.1%

Phase 3

Cataract

Rimexolone

Phase 3

Dry Eye

AL-4943A Ophthalmic Solution Vehicle

Phase 3

Allergic Conjunctivitis

AL-4943A ophthalmic solution

Phase 3

Allergic Conjunctivitis

Ofloxacin otic solution

Phase 3

Acute Otitis Media

Difluprednate 0.05% ophthalmic emulsion

Phase 3

Endogenous Anterior Uveitis

Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution

Phase 3

Glaucoma, Open-angle

Brinzolamide 1% ophthalmic suspension

Phase 3

Open-Angle Glaucoma

Difluprednate ophthalmic emulsion, 0.05%

Phase 3

Cataracts

Travoprost 0.004%/Timolol 0.5%

Phase 3

Open-angle Glaucoma

Travoprost 0.004% with and without BAK

Phase 3

Open-angle Glaucoma

Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension

Phase 3

Cataract

Travoprost, Investigational

Phase 3

Open-angle Glaucoma

Next Generation Ophthalmic Irrigating Solution (NGOIS)

Phase 3

Cataract

Tobramycin 0.3%/Dexamethasone 0.05%

Phase 3

Ocular Inflammation Associated With Blepharaconjunctivitis

Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension

Phase 3

Open-Angle Glaucoma

Brinzolamide ophthalmic suspension, 1%

Phase 3

Open-Angle Glaucoma

0.003% AR-15512 ophthalmic solution

Phase 3

Dry Eye Disease

Anecortave Acetate Sterile Suspension, 75 mg/mL

Phase 3

Open-angle Glaucoma

anecortave acetate

Phase 3

Macular Degeneration

Tobradex AF

Phase 3

Cataract

EXE844 Sterile Otic Suspension, 0.3%

Phase 3

Otitis Media With Effusion in Children

Travoprost (0.004%)

Phase 3

Glaucoma, Open-Angle

Sodium Hyaluronate Ophthalmic Solution, 0.18%

Phase 3

Dry Eye Syndrome

Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%

Phase 3

Bacterial Conjunctivitis

Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension

Phase 3

Open-Angle Glaucoma

Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension

Phase 3

Open-Angle Glaucoma

Alcon Investigational Agent

Phase 3

Open-Angle Glaucoma

Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)

Phase 3

Open-angle Glaucoma

Brimonidine Tartrate Ophthalmic Solution

Phase 3

Open-Angle Glaucoma

Latanoprost (0.005%)

Phase 3

Glaucoma, Angle-Closure

0.003% AR-15512

Phase 3

Dry Eye Disease

Nepafenac ophthalmic solution 0.1%

Phase 3

Cataract

Anecortave Acetate Sterile Suspension, 30 mg/mL

Phase 3

Macular Degeneration

FID 123320 Ophthalmic Solution

Phase 3

Ocular Redness

Brolucizumab ophthalmic solution

Phase 3

Neovascular Age-Related Macular Degeneration

Moxidex otic solution

Phase 3

Acute Otitis Media

IOP Lowering Medications

Phase 3

Open-Angle Glaucoma

Olopatadine Hydrochloride Ophthalmic Solution 0.2%

Phase 3

Allergic Conjunctivitis

Moxifloxacin otic solution

Phase 3

Acute Otitis Media

Anecortave Acetate 15 mg sterile suspension

Phase 3

Macular Degeneration

Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution

Phase 3

Open Angle Glaucoma

BETAXON (levobetaxolol HCl)

Phase 3

Glaucoma

Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution

Phase 3

Ocular Hypertension

Travoprost APS 40 micrograms/ml eye drop solution

Phase 3

Open Angle Glaucoma

Travoprost

Phase 3

Glaucoma, Open-Angle

Ocriplasmin

Phase 3

Symptomatic Vitreomacular Adhesion

LME636 60 mg/mL ophthalmic solution

Phase 2

Acute Anterior Uveitis

Anecortave acetate 30 mg

Phase 2

AMD

AL-3789 Sterile Suspension

Phase 2

Open-angle Glaucoma

LME636 ophthalmic solution

Phase 2

Dry Eye

AL-38583 ophthalmic solution

Phase 2

Allergic Conjunctivitis

Ranibizumab 0.5 mg

Phase 2

Exudative Age-Related Macular Degeneration

Travoprost ophthalmic solution, 0.0008%

Phase 2

Open-angle Glaucoma

Xalatan

Phase 2

Open-Angle Glaucoma

AL-37807 ophthalmic suspension, 0.1%

Phase 2

Open-Angle Glaucoma

Aflibercept

Phase 2

Exudative Age-Related Macular Degeneration

Combination IOP Lowering Therapy

Phase 2

Glaucoma, Open-angle

Anecortave Acetate Sterile Suspension, 6 mg/mL

Phase 2

Eye Diseases

Travoprost/brinzolamide

Phase 2

Open-angle Glaucoma

LHA510 ophthalmic suspension

Phase 2

Exudative Age-Related Macular Degeneration

AL-39256 Ophthalmic Suspension, 1%

Phase 2

Open-Angle Glaucoma

AL-39324 ophthalmic suspension

Phase 2

Age Related Macular Degeneration

AR-17043 Ophthalmic Solution

Phase 2

Open Angle Glaucoma

Travoprost Ophthalmic Solution, 0.00013%

Phase 2

Open-angle Glaucoma

Travoprost ophthalmic solution (new formulation)

Phase 2

Ocular Hypertension

Brolucizumab 3 mg/50 μL

Phase 2

Neovascular Age-Related Macular Degeneration

Dose Level A / Brinzolamide 1% ophthalmic suspension

Phase 2

Glaucoma

ESBA1008 solution

Phase 2

Exudative Age-Related Macular Degeneration

ESBA105 ophthalmic solution

Phase 2

Eyes Dry Chronic

AL-53817 Ophthalmic Solution, 0.1%

Phase 2

Allergic Conjunctivitis

AR-14034 SR implant lower dose

Phase 2

Neovascular Age-related Macular Degeneration (nAMD)

AL-78898A

Phase 2

Exudative Age-Related Macular Degeneration

AL-37807 Ophthalmic Suspension, 1.0%

Phase 2

Open-angle Glaucoma

Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel

Phase 2

Dry Eye

Travoprost Vehicle

Phase 2

Open-angle Glaucoma (OAG)

AL-12182 0.003% Ophthalmic Solution

Phase 2

Open-angle Glaucoma

AL-37807

Phase 2

Open-Angle Glaucoma

Brinzolamide/Timolol

Phase 2

Open-angle Glaucoma

MGV354 ophthalmic suspension

Phase 2

Ocular Hypertension

AL-38583 ophthalmic solution 0.05%

Phase 2

Dry Eye

Glaucoma therapy

Phase 2

Open-Angle Glaucoma

CLG561

Phase 2

Geographic Atrophy

Hydroxypropyl Guar Galactomannan

Phase 2

Dry Eye Disease

AL-54478 0.005%

Phase 2

Open-angle Glaucoma (OAG)

Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply